CNR1 and Parkinson disease: In the field of Parkinson’s disease research, it is increasingly recognized that targeting neuronal CB1R-GPR55 and CB2R-GPR55 heteromers with cannabinoids can be a successful therapeutic approach to both manage symptoms and delay disease progression [62,63].